1 Month Followup - Pedimacs

Size: px
Start display at page:

Download "1 Month Followup - Pedimacs"

Transcription

1 version date: 03/27/ Month Followup - Pedimacs Followup Status (1 Month Followup (+/- 7 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information Follow-up date Facility Type Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility State reason why you are unable to obtain follow-up information Patient didn't come to clinic t able to contact patient t addressed by site Was patient intubated? Was patient on dialysis? Pump Change Pump Exchange If yes, please select one of the following: Please select appropriate reason: Intracorporeal device Para- or Extra- corporeal device Upsizing device because of patient growth status All other reasons would categorize the pump change as a Device Malfunction Thrombus NOT associated with hemolysis Change in hemodynamics Clinical status Device parameters Was there a Console Change? 1 of 13

2 1 Month Followup - Status version date: 03/27/2018 Date of console change ST= Original Console Name New Console Name Medical Condition NYHA Class Class I: limitation of physical activity; physical activity does not cause fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitations or shortness of breath. Class III: Marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation or shortness of breath. Class IV: Unable to carry on minimal physical activity without discomfort; symptoms may be present at rest. Ross Classification of Congestive Heart Failure Ross Class I: limitations or symptoms. Ross Class II: growth failure. Ross Class III: Growth failure. Ross Class IV: Symptomatic at rest. t applicable: >= 2 years of age Choose all indicated symptoms that apply. Choose all indicated symptoms that apply. Choose all indicated symptoms that apply. Mild tachypnea with feeds in infant Mild diaphoresis with feeds in infant Dyspnea on exercise in older children Marked tachypnea with exertion or with feeding Marked diaphoresis with exertion or with feeding Tachypnea Retractions Grunting Diaphoresis Functional Capacity Sedated Paralyzed Intubated 2 of 13

3 1 Month Followup - Status version date: 03/27/2018 Ambulating Primary Nutrition Orally Per feeding tube TPN t Applicable Excursions Has the patient had any nonmedically required excursions off the unit? If yes, where (please select all that apply) t Applicable Playroom Cafeteria Walk outside Sitting room General rehab ne ZONES Hemolysis Zone Please enter the peak Plasma-free hemoglobin (PFH) since the last visit: ST= t Done What is your hospital s upper limit of the normal range of peak PFH? ST= t Done Please enter the peak serum lactate dehydrogenase (LDH) since the last visit: ST= t Done What is your hospital s upper limit of the normal range of LDH? ST= t Done Enter the Maximum and Minimum HCT or HGB since the last visit. Min. HCT: ST= t Done 3 of 13

4 1 Month Followup - Status version date: 03/27/2018 Max. HCT: ST= t Done Min. HGB: ST= t Done Max. HGB: ST= t Done Highest Total Bilirubin since the last visit: ST= t Done Has the following been present at any time since the last visit? Physical Findings (select all that apply): Hemoglobinuria (Tea-Colored Urine)? Pump malfunction and/or abnormal pump parameters? Right Heart Failure Zone Clinical Findings Since the last visit. CVP or RAP > 16 mmhg? t Done Dilated Vena Cava with absence of Inspiratory Variation by Echo? t Done Clinical findings of elevated jugular venous distension at least half way up the neck in an upright patient? Peripheral Edema? Ascites? 4 of 13

5 1 Month Followup - Status version date: 03/27/2018 Has the patient been on Inotropes since the last visit? If yes, select all that apply: Dopamine Dobutamine Milrinone Isoproterenol Epinephrine repinephrine Levosimendan Vasopressin Nitroprusside Fenoldopam Prostacyclin Nesiritide? Has the patient had a RVAD implant since the last visit? Has the patient experienced a Neurological Event since time of implant? If yes, please enter the Modified Rankin Scale. Modified Rankin Scale 0 symptoms at all 1 - Significant disability: despite symptoms: able to carry out all usual duties and activities 2 - Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance 3 - Moderate disability: requiring some help, but able to walk without assistance. 4 - Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance. 5 - Severe disability: bedridden, incontinent and requiring constant nursing care and attention. 6 - Dead ST= t Documented t Done 5 of 13

6 version date: 03/27/ Month Followup - Pedimacs Hemodynamics General Hemodynamics Systolic blood pressure ST= t done mmhg Diastolic blood pressure ST= t done mmhg Mean Arterial Blood Pressure (MAP) mmhg ST= t done ECG rhythm Sinus Atrial fibrillation Atrial Flutter Paced: Atrial pacing Paced: Ventricular pacing Paced: Atrial and ventricular pacing t done Other, specify Height ST= t done in cm Weight ST= t done lbs kg Invasive Hemodynamics Date of Measurement ST= t Done Pulmonary artery systolic pressure ST= t Done mmhg 6 of 13

7 1 Month Followup - Hemodynamics version date: 03/27/2018 Pulmonary artery diastolic pressure ST= t Done mmhg Mean RA Pressure ST= t Done mmhg PVR wood units ST= t Done Mean Pulmonary artery wedge pressure ST= t Done mmhg Central venous pressure (CVP) mmhg ST= t Done Cardiac Index ST= t Done L/min/M 2 (by Swan) Was Cardiac Index Measured by Fick or Thermodilution? Choose Method Fick Thermodilution 7 of 13

8 version date: 03/27/ Month Followup - Pedimacs Medications Was the patient sent home with an IV? ACE inhibitors Aldosterone antagonist Amiodarone Angiotensin receptor blocker drug Antiplatelet therapy drug Select drug(s) Aspirin Dextran Dipyridamole Clopidogrel Ticlopidine Other, specify Thrombolytic Beta-blockers Calcium channel blockers Digoxin 8 of 13

9 1 Month Followup - Medications version date: 03/27/2018 Hydralazine Loop diuretics If yes, enter dosage: mg/day ST= Type of Loop Diuretic: Furosemide Torsemide Bumetanide Other Low molecular weight heparin (Lovenox, Fragmin, Innohep) Nitric oxide Sildenafil/ Bosentan UFH: Unfractionated Heparin Warfarin (coumadin) Arixtra (fondaparinux) Did patient receive new IV or oral medication to treat hypertension? Transfusion Was there a Tranfusion? If yes, enter number of PRBC (Total number of cc's received) ST= 9 of 13

10 version date: 03/27/ Month Followup - Pedimacs Laboratory Sodium meq/l ST= t done mmol/l Potassium meq/l ST= t done mmol/l Blood urea nitrogen mg/dl ST= t done mmol/l Creatinine mg/dl ST= t done umol/l SGPT/ALT (alanine aminotransferase/alt) ST= t done u/l SGOT/AST (aspartate aminotransferase/ast) ST= t done u/l LDH units/l, U/L, ukat/l ST= t done Total bilirubin mg/dl ST= t done umol/l Bilirubin direct mg/dl ST= t Done umol/l 10 of 13

11 1 Month Followup - Laboratory version date: 03/27/2018 Bilirubin indirect mg/dl ST= t Done umol/l Albumin g/dl ST= t done g/l Pre-albumin mg/dl ST= t done mg/l Total Cholesterol ST= < 50 mg/dl t done mg/dl mmol/l Brain natriuretic peptide BNP ST= > 7500 pg/ml t done pg/ml ng/l NT pro brain natriuretic peptide Pro- BNP ST= t done pg/ml ng/l White blood cell count ST= t done x10 3 /ul x10 9 /ul Reticulocyte count % ST= t Done Hemoglobin g/dl ST= t done g/l mmol/l 11 of 13

12 1 Month Followup - Laboratory version date: 03/27/2018 Hemoglobin A1C % Estimated Average Glucose (eag): ST= t Done mmol/mol mg/dl mmol/l Platelets ST= t done x10 3 /ul x10 9 /ul INR international units ST= t done Plasma-free hemoglobin mg/dl ST= t Done g/l Positive antiheparin/platelet antibody (HIT) If, are they on direct thrombin inhibitors If, Enter Drugs: Aspirin Dipyridamole Plavix Heparin Coumadin Direct thrombin inhibitors (ex: arg, lip, val ) Was a TEG done? ThrombElastoGraph Hemostasis System (TEG) profile, MA k ThrombElastoGraph Hemostasis System (TEG) profile, R k ST= t Done ST= t Done max amplitude in kaolin reaction time in kaolin 12 of 13

13 1 Month Followup - Laboratory version date: 03/27/2018 ThrombElastoGraph HemostasisSystem (TEG) profile, R h ST= t Done reaction time w/heparinase CRP or hs-crp ST= t done mg/dl Lupus Anticoagulant Positive Negative 13 of 13

Inpatient Outpatient Other Facility Unable to obtain follow up information

Inpatient Outpatient Other Facility Unable to obtain follow up information version date: 12/10/2015 1 Month Followup Followup Status (1 Month Followup (+/ 7 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow up information Follow up

More information

1 Week Followup - Intermacs

1 Week Followup - Intermacs version date: 9/27/2017 1 Week Followup - Intermacs Followup Status (1 Week Followup (+/- 3 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information

More information

1 Week Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown

1 Week Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown 1 Week Followup t Started Please answer all questions considering all time since the previous visit and current follow-up date. Print this Form Followup Status t Started Select one of the following Inpatient

More information

Followup Status (1 Week Followup (+/- 3 days))

Followup Status (1 Week Followup (+/- 3 days)) 1 Week Followup - Status version date: 09/27/2018 Intermacs 1 Week Followup Followup Status (1 Week Followup (+/- 3 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain

More information

Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown

Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown 3 Month Followup t Started Please answer all questions considering all time since the previous visit and current follow-up date. Print this Form Followup Status t Started Select one of the following Inpatient

More information

3 Month / 6 Month Follow-Up

3 Month / 6 Month Follow-Up 3 Month / 6 Month Follow-Up Select one of the following:* Follow-up date:* Facility Type:* State reason why you are unable to obtain follow-up information:* General Hemodynamics - during report interval

More information

: 2014 INTERMACS 4.0 Launches June 2, 2014

: 2014 INTERMACS 4.0 Launches June 2, 2014 : 2014 INTERMACS 4.0 Launches June 2, 2014 David C. Naftel, PhD 1 June 2006 March 2014 UAB: DCC UNOS: WBDE 2 : 2006 What patients are receiving MCSDs? Do DT patients ever receive a transplant? What are

More information

Adverse Event Not Started

Adverse Event Not Started Adverse Event t Started Adverse Event Status Print this Form t Started Please enter the date of the event you are reporting: Please enter a label describing this event: 2014 InterMACS [InterMACS_New] 1

More information

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart

More information

3 Month Followup - Intermacs

3 Month Followup - Intermacs 3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information Follow-up date Facility

More information

3 Month Followup - Intermacs

3 Month Followup - Intermacs 3 Month Followup - Status version date: 06/28/2018 3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to

More information

3 Month Followup - Intermacs

3 Month Followup - Intermacs version date: 12/19/2017 3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information

More information

Pre-Implant. Demographics Height:* in cm ST = Weight:* lbs kgs ST = Blood type:*

Pre-Implant. Demographics Height:* in cm ST = Weight:* lbs kgs ST = Blood type:* Pre-Implant Demographics Height:* in cm ST = Weight:* lbs kgs ST = Blood type:* Medical Support Status Current Device Strategy at time of implant:* Enter List Date:* mm/dd/yyyy ST= Concerns / Contraindications

More information

Followup Status (3 Month Followup (+/- 1 month))

Followup Status (3 Month Followup (+/- 1 month)) 3 Month Followup - Status version date: 09/27/2018 Intermacs 3 Month Followup Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to

More information

GWTG Post-Discharge Follow-up Form

GWTG Post-Discharge Follow-up Form Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health

More information

Heart Failure. Dr. William Vosik. January, 2012

Heart Failure. Dr. William Vosik. January, 2012 Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Adverse Event - Intermacs

Adverse Event - Intermacs version date: 6/28/2017 Adverse Event - Intermacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 24 version date: 6/28/2017

More information

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea) Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Form 8: Post Transplant Annual Followup

Form 8: Post Transplant Annual Followup Page 1 of 8 Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 8: Post Transplant Annual Followup Toggle Question Year/Info Print this Form t Started

More information

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure: Guideline-Directed Management and Therapy Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the

More information

Medical Management of Acute Heart Failure

Medical Management of Acute Heart Failure Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training

More information

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received

More information

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College

More information

Adverse Event - Pedimacs

Adverse Event - Pedimacs version date: 12/19/2017 Adverse Event - Pedimacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 22 version date: 12/19/2017

More information

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40% Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM ID NUMBER: FORM NAME: H F A DATE: 10/01/2015 VERSION: D CONTACT YEAR NUMBER: FORM SEQUENCE NUMBER: General Instructions: The Heart Failure Hospital Record

More information

Adverse Event. Adverse Event Status. version date: 12/10/ of 21. Please enter the date of the event you are reporting:

Adverse Event. Adverse Event Status. version date: 12/10/ of 21. Please enter the date of the event you are reporting: version date: 12/10/2015 Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 21 version date: 12/10/2015 Adverse Event

More information

Form 8: Post Transplant Annual Followup

Form 8: Post Transplant Annual Followup Page 1 of 7 Show trials/registries Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 8: Post Transplant Annual Followup Print this Form t Started 1

More information

Adverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:

Adverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event: Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 17 Adverse Event Infection Was there a major infection? Date of

More information

IN-HF on line: patient settings (Enrollement period= )

IN-HF on line: patient settings (Enrollement period= ) IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients

More information

Ventricular Assist Devices

Ventricular Assist Devices Page 1 By Tonya Elliott, RN, MSN Background, Indications for VADs Mechanical circulatory support has become an acceptable therapy for end stage heart failure (HF) in maximally medically treated patients

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Pre-discussion questions

Pre-discussion questions Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280

Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Instructions: Review PVDOMICS MOP Chapter 100 prior to completing right

More information

4 Has this patient been transplanted No

4 Has this patient been transplanted No Form 1RL: Relisting Print this Form t Started 1 Date of Relisting Height and Weight 2 Height Centimeters Inches Calculated BSA: n/a BMI: n/a 3 Weight Kilograms Pounds 4 Has this patient been transplanted

More information

Volume 3 (2017) Issue 23 ISSN Abstract. Keywords. Learning Objective. Introduction. Open Journal of Clinical & Medical Case Reports

Volume 3 (2017) Issue 23 ISSN Abstract. Keywords. Learning Objective. Introduction. Open Journal of Clinical & Medical Case Reports Open Journal of Clinical & Medical Case Reports Volume 3 (2017) Issue 23 ISSN 2379-1039 Severe pulmonary hypertension secondary to anagrelide treatment? George Calcaianu*; Mihaela Calcaianu; Guillaume

More information

5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none

5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none Disclosure: Pulmonary Hypertension none James Ramsay MD Medical Director, CV ICU, Moffitt Hospital, UCSF PULMONARY HYPERTENSION mean PAP > 25 mmhg at rest Pulmonary Hypertension and Right Ventricular Dysfunction:

More information

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body

More information

Cardiorenal and Renocardiac Syndrome

Cardiorenal and Renocardiac Syndrome And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

Tables of Normal Values (As of February 2005)

Tables of Normal Values (As of February 2005) Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal

More information

Patient Encounters in the Primary Care Setting

Patient Encounters in the Primary Care Setting Patient Encounters in the Primary Care Setting Carmine D Amico, D.O. Clinical Cases Overview Learning objectives Clinical case presentations Questions for audience participation 1 Clinical Cases Learning

More information

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure? Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,

More information

Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes Yes Unknown

Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes Yes Unknown Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes HbA1c If medication; - Insulin - Oral antidiabetic - Both - Diet - treatment : Fasting blood sugar 7 mmol/l or post glucose 11.1 mmol/l and/or

More information

Acute heart failure, beyond conventional treatment: persisting low output

Acute heart failure, beyond conventional treatment: persisting low output Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts

More information

Topic Page: congestive heart failure

Topic Page: congestive heart failure Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation

More information

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:

More information

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate

More information

Heart Failure. Dr. Alia Shatanawi

Heart Failure. Dr. Alia Shatanawi Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Recent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine

Recent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria

More information

SA XXXX Special Authority for Subsidy

SA XXXX Special Authority for Subsidy SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH

More information

Exercise Prescription for Patients with CHF

Exercise Prescription for Patients with CHF Exercise Prescription for Patients with CHF LESLIE AYRES, PT, DPT Goals After viewing this presentation the physical therapist will be able to: Discuss and understand the diagnosis of CHF including: Clinical

More information

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6

More information

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl

More information

3.1 Name of the Source of Registration (OPD/ICU/Ward Name) Hospital Registration Number OPD Number...

3.1 Name of the Source of Registration (OPD/ICU/Ward Name) Hospital Registration Number OPD Number... NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH Indian Council of Medical Research, Bengaluru (A Study on the Magnitude and Pattern of Causes of Heart Failure A Feasibility Study) I IDENTIFYING INFORMATION

More information

Nothing to Disclose. Severe Pulmonary Hypertension

Nothing to Disclose. Severe Pulmonary Hypertension Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis

More information

POST-OP CARDIAC SURGERY PHYSICIAN S ORDER SHEET USE BALLPOINT PEN ONLY. CARDIAC INTENSIVE CARE UNIT

POST-OP CARDIAC SURGERY PHYSICIAN S ORDER SHEET USE BALLPOINT PEN ONLY. CARDIAC INTENSIVE CARE UNIT PHYSICIAN S SHEET Automatically Activate, if not in agreement, cross out and initial Activated by Checking Box ALLERGIES: None known YES Patient s Height: Patient s Weight: ALL MEDICATION and INTRAVENOUS

More information

CCRN Review Cardiovascular

CCRN Review Cardiovascular CCRN Review Cardiovascular Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Angina Definition discomfort that occurs when oxygen demand

More information

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta

Diagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations

More information

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms

More information

Heart Failure Update John Coyle, M.D.

Heart Failure Update John Coyle, M.D. Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and

More information

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension

More information

MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center

MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE Mitral Valve Regurgitation Mitral Valve Stenosis Mitral Valve Prolapse MITRAL REGURGITATION

More information

HF Patient Management Tool July 2017

HF Patient Management Tool July 2017 Heart Failure Form Page 1 PMT FORM SELECTION HF ARRIVAL AND ADMISSION INFORMATION Patient ID: Legend: Elements in bold are required Internal Tracking ID: Physician/Provider NPI: Arrival Date and Time:

More information

CASE DISCUSSION. Dr JAYASREE VEERABOINA 2nd yr PG MS OBG

CASE DISCUSSION. Dr JAYASREE VEERABOINA 2nd yr PG MS OBG CASE DISCUSSION Dr JAYASREE VEERABOINA 2nd yr PG MS OBG Normal Cardiovascular changes in Pregnancy CARDIAC OUTPUT 5 th wk -- starts 12 wks -- 30-35% 30-32 wks -- 40% During labour -- 50% After delivery

More information

DAY1_CARDIOVASCULAR PRACTICE QUESTIONS

DAY1_CARDIOVASCULAR PRACTICE QUESTIONS DAY1_CARDIOVASCULAR PRACTICE QUESTIONS 1 P age 1. A 59-year-old male is admitted complaining of chest pain and dyspnea. ST elevation and T-wave inversion were seen on the ECG in V2, V3, and V4. IV thrombolytic

More information

Summary/Key Points Introduction

Summary/Key Points Introduction Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification

More information

Cardiac Disease in Fatty Acid Oxidation Disorders

Cardiac Disease in Fatty Acid Oxidation Disorders Cardiac Disease in Fatty Acid Oxidation Disorders Kathryn Chatfield, MD, PhD Assistant Professor of Pediatrics Division of Cardiology University of Colorado School of Medicine Children s Hospital Colorado

More information

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph

More information

6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center

6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center RATE Abciximab (Reopro) Alteplase (tpa, Activase) All units 6S and 6W ONLY Platelet aggregation inhibitor Thrombolytic agent Bolus: 0.25 mg/kg IV over 5 min Infusion: 0.125 0.9 mg/kg (max 90 mg); 10% of

More information

Module 1: Evidence-based Education for Health Care Professionals

Module 1: Evidence-based Education for Health Care Professionals Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

Understanding Blood Tests

Understanding Blood Tests PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away

More information

Restrictive Cardiomyopathy in Cats (a Type of Heart-Muscle Disease) Basics

Restrictive Cardiomyopathy in Cats (a Type of Heart-Muscle Disease) Basics Restrictive Cardiomyopathy in Cats (a Type of Heart-Muscle Disease) Basics OVERVIEW The heart of the cat is composed of four chambers; the top two chambers are the left and right atria and the bottom two

More information

Heart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients

Heart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients Focus on CME at the University of Université Manitoba de Sherbrooke By Anne Fradet, MD, FRCP, CSPQ Severe Heart Failure What you can do for your patients The case of Mr. White Mr. White, 72, comes to your

More information

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias

Dysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias Dysrhythmias Dysrythmias & Anti-Dysrhythmics Rhythm bad in the heart: Whitewater rafting Electrical impulses coordinate heart Reduction in Cardiac Output PEA Asystole Components of an ECG Wave EKG Parameters

More information

2016 Update to Heart Failure Clinical Practice Guidelines

2016 Update to Heart Failure Clinical Practice Guidelines 2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes

More information

i. Where is the participant seen?

i. Where is the participant seen? PFU01 method used: Phone/in-person interview 1 Enter PIP # here: Online survey 2 Enter Web # here: Initials of person completing form: Date Form Completed: / / Form Version: 03 / 01 / 18 Is the participant

More information

HEART FAILURE. Study day November 2018 Sarah Briggs

HEART FAILURE. Study day November 2018 Sarah Briggs HEART FAILURE Study day November 2018 Sarah Briggs Overview and Introduction This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure

More information

B. PANITUMUMAB DOSE LEVEL 0 No dose reduction 1 Level -1 2 Level Other, specify in comments for this cycle

B. PANITUMUMAB DOSE LEVEL 0 No dose reduction 1 Level -1 2 Level Other, specify in comments for this cycle Radiation Therapy Oncology Group Phase II Study Pre-operative Chemo- Radiation + Panitumumab for Potentially Operable Lung Cancer Concurrent Summary Form AMENDED DATA YES INSTRUCTIONS: Submit all pages

More information

Heart Failure 101 The Basic Principles of Diagnosis & Management

Heart Failure 101 The Basic Principles of Diagnosis & Management Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence

More information

Heart failure hospitalizations with preserved or reduced ejection fraction

Heart failure hospitalizations with preserved or reduced ejection fraction Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,

More information

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF

Heart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange

More information

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for

Heart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange

More information

Peripartum Cardiomyopathy. Lavanya Rai Manipal

Peripartum Cardiomyopathy. Lavanya Rai Manipal Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting

More information

Hemodynamic Monitoring

Hemodynamic Monitoring Perform Procedure And Interpret Results Hemodynamic Monitoring Tracheal Tube Cuff Pressure Dean R. Hess PhD RRT FAARC Hemodynamic Monitoring Cardiac Rate and Rhythm Arterial Blood Pressure Central Venous

More information

CHAPTER-I MYOCARDIAL INFARCTION

CHAPTER-I MYOCARDIAL INFARCTION CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply

More information

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities

More information